The ability of trimetazidine (2,3,4, trimethoxybenzylpiperazine dihydrochloride, TMZ) to protect the myocardium against anthracycline (ANT)-induced cardiotoxicity during chemotherapy has been evaluated in female patients with breast cancer. A clinical trial was conducted in 61 patients subdivided into three groups: group 1 (n = 15, G1) treated with standard ANT protocol and cardioprotection by dexrazoxane (DEX) plus TMZ (60 mg, daily dose); group 2 (n = 22, G2) treated with ANT and cardioprotection by TMZ only; and group 3 (n = 24, G3) scheduled to receive ANT therapy and DEX. All the patients submitted to an echocardiographic evaluation of diastolic function (E wave velocity, A wave velocity, isovolumetric relaxation time [IVRT], deceleration time [DT]) at enrollment (TO), at T1 time, at T2 time, and at T3 time. After a 12- month follow-up period, the patients showed a good conservation of diastolic function both in G1 and G2 groups. No statistically significant difference was observed in E wave and A wave velocity and E/A ratio after ANT treatment. TMZ produced a cardioprotective effect, compa rable to DEX protection, against subacute and chronic subclinical cardiotoxicity with no signif icant changes in diastolic function after 1 year of follow-up.
Get full access to this article
View all access options for this article.
References
1.
Singh B.: Mechanism of action of a novel metabolically active antianginal agent (trimetazidine) delineated by PET. J Am Coll Cardiol27:132A, 1996 .
2.
Maridonneau Parini I., Harpey C.: Effects of trimetazidine on membrane damage reduced by oxygen free radicals in human red cells. Br J Clin Pharmacol20:148-151, 1985.
3.
Detry JM, Sellier P., Pennaforte S., et al, on behalf of the Trimetazidine European Multicenter Study Group: Trimetazidine: A new concept in the treatment of angina. Comparison with propranolol in patients with stable anginaBr J Clin Pharmacol37: 279-288, 1994.
4.
Detry JM, Leclerq BS: Trimetazidine European multicenter study vs. propranolol in stable angina pectoris ; contribution of Holter electrocardiographic ambulatory monitoring . Am J Cardiol76:8B-11B, 1995.
5.
Michaelides AP, Vyssoulis GP, Bonoris PE, et al: Beneficial effects of trimetazidine in men with stable angina under beta blocker treatment. Curr Ther Res46:565-576, 1989.
6.
Steg PG, Grollier G., Galley P., et al: A randomized double-blind trial of trimetazidine as adjunctive therapy to primary PTCA for acute myocardial infarction: evidence for improved myocardial reperfusion from ST-segment analysis. Eur Heart J19:2046, 1998.
7.
Kober G., Buck T., Sievert H., et al: Myocardial protection during percutaneous transluminal coronary angioplasty : Effects of trimetazidine. Eur Heart J13:1109-1115, 1992.
8.
Belardinelli M., Purcaro A.: Trimetazidine improves the contractile response of hibernating myocardium to low-dose dobutamine in ischemic cardiomyopathy . Circulation98:3727, 1998.
9.
Lu C., Dabrowski P., Fragasso G., et al: Effects of trimetazidine on ischemic left ventricular dysfunction in patients with coronary artery disease. Am J Cardiol82:898-901, 1998.
10.
Bristow MR, Billingham ME, Mason JW, et al: Clinical spectrum of anthracycline antibiotic cardiotoxicity . Cancer Treat Rep62:873-879, 1978.
11.
Schwartz R. , Mc Kenzie W., Alexander J., et al: Congestive heart failure and left ventricular dysfunction complicating Doxorubicin therapy: A seven year experience using serial radionuclide angiocardiography. Am J Med82:1109-1118, 1987.
12.
Mortensen SA , Olsen HS, Baandrup U.: Chronic anthracycline cardiotoxicity; hemodynamic and histopathological manifestations suggestive a restrictive endomyocardial disease. Br Heart J55:274-282, 1986.
13.
Praga C., Beretta G., Vigo PL: Adriamycin cardiotoxicity : A survey of 1273 patients. Cancer Treat Rep63:827-834, 1979.
14.
Von Hoff DD, Layard MW, Basa P.: Risk factors for doxorubicin induced congestive heart failure. Ann Intern Med91:710-717, 1979.
15.
Speyer JL, Green MD, Zeleniuch Jacquotte A.: ICRF-187 permits longer treatment with doxorubicin in women with breast cancer . J Clin Oncol10:117-127, 1982.
16.
Venturini M. , Michelotti A., Del Mastro L.: Multicenter randomized controlled clinical trial to evaluate cardioprotection of dexrazoxane versus no cardioprotection in women receiving epirubicin chemotherapy for advanced breast cancer. J Clin Oncol14:3112: 3120, 1996.
17.
Lopez M., Vici P.: European trials with dexrazoxane in amelioration of doxorubicin and epirubicin-induced cardiotoxicity. Semin Oncol25(4 suppl):10:55-60, 1998.
18.
Nishimura RA , Tajik AJ: Quantitative hemodynamics by Doppler echocardiography: A noninvasive alternative to cardiac catheterization. Progr Cardiovasc Dis36:309-342, 1994.
19.
Vasan RS, Benjamin EJ, Levy D.: Prevalence, clinical features and prognosis of diastolic heart failure: An epidemiologic perspective. J Am Coll Cardiol26: 1565-1574, 1995.
20.
European Study Group on Diastolic Heart Failure : How to diagnose diastolic heart failure. Eur Heart J19:990-1003, 1998.
21.
Takatsuji H. , Mikami J., Urasawa K., et al: A new approach for evaluation of left ventricular diastolic function: Spatial and temporal analysis of left ventricular filling flow propagation by color M-mode Doppler echocardiography. J Am Coll Cardiol27:365-371, 1996.
22.
Lee BH, Goodenday LS, Muswick GJ, et al: Alterations in left ventricular diastolic function with doxorubicin therapy. J Am Coll Cardiol9:184-188, 1987.
23.
Marchandise B., Scroeder E., Bosly , et al: Early detection of doxorubicin cardiotoxicity: Interest of Doppler echocardiographic analysis of left ventricular filling dynamics. Am Heart J118:92-98, 1989.
24.
Brown KA, Blow AJ, Weiss RM, et al: Acute effects of doxorubicin on human left ventricular systolic and diastolic function. Am Heart J118:92-98, 1989.
25.
Alexander J. , Dainiak N., Berger HJ, et al: Serial assessment of doxorubicin cardiotoxicity with quantitative radionuclide angiocardiography . N Engl J Med300:278-283, 1979.
26.
Stoddard HF , Seeger J., Liddel NE, et al: Prolongation of isovolumetric relaxation time as assessed by Doppler echocardiography predicts doxorubicin-induced systolic dysfunction in humans. J Am Coll Cardiol20:62-69, 1992.
27.
Allen A.: The cardiotoxicity of chemotherapeutic drugs. Semin Oncol19:529-542, 1992.
28.
Lopez M., Vici P., Di Lauro L., et al: Randomized prospective clinical trial of high dose epirubicin and dexrazoxane in patients with advanced breast cancer and soft tissue sarcoma . J Clin Oncol16:89-92, 1998.
29.
Levy S., Group of South France Investigators.Combination therapy of trimetazidine with diltiazem in patients with coronary artery disease . Am J Cardiol76:6B-12B, 1995.
30.
Fantini E., Demaison L., Sentax E., et al: Some biochemical aspects of the protective effect of trimetazidine on rat cardiomyocites during hypoxia and reoxygenation. J Mol Cell Cardiol26:949-958, 1994.
31.
Allibardi S. , Chierchia SL, Cerioli V., et al: Trimetazidine reduces post-ischemic dysfunction in rat hearts by decreasing energy requirements during underperfusion . J Cardiovasc Pharmacol22:640-647, 1998.
32.
Detry MJ: TEMS: Double-blind comparison of trimetazidine and propranolol in stable angina pectoris. J Am Coll Cardiol31:36-47, 1998.
33.
Morin D., Sapena R., Elimadi A., et al: [(3)H]-trimetazidine mithocondrial binding sites: Regulation by cations, effect of trimetazidine derivatives and other agents and interaction with an endogenous substance. Br J Pharmacol130:655-663, 2000.
34.
Kantor PF, Lucien A., Kozak R., et al: The antianginal drug trimetazidine shifts cardiac energy metabolism from fatty acid oxidation to glucose oxidation by inhibiting mithocondrial long-chain 3-ketoacyl coenzyme A thiolase. Circ Res17;86(5):580-585, 2000.
35.
Leandro J., Dyck J., Poppe D., et al: Cardiac dysfunction late after cardiotoxic therapy for childhood cancer. Am J Cardiol74:1152-1156, 1994 .
36.
Bu'Lock FA, Mott MG, Oakhill A., et al: Left ventricular diastolic function after anthracycline chemotherapy in childhood: Relation with systolic function, symptoms and pathophysiology . Br Heart J73:340-350, 1995.
37.
Cittadini A. , Fazio S., D'Ascia C., et al: Subclinical cardiotoxicity by doxorubicin: A pulsed Doppler echocardiographic study. Eur Heart J12:1000-1005, 1999.
38.
Lefrak EA, Pitha J., Rosenheim S.: A clinicopathologic analysis of adriamycin cardiotoxicity. Cancer32:302-314, 1973.
39.
Wyatt HL, Haendchen RV, Meerbaum S., et al: Assessment of quantitative methods for 2-dimensional echocardiography . Am J Cardiol5:396-401, 1983.
